Stocktoria
Larimar Therapeutics, Inc. LRMR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-06-19
Larimar Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $154.2M | $73.3M | $27.7M | $24.2M | $38.4M |
| Operating income | -$172.5M | -$90.9M | -$41.8M | -$36.5M | -$50.5M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$165.7M | -$80.6M | -$36.9M | -$35.4M | -$50.6M |
| EPS (diluted) | — | $-1.32 | $-0.84 | $-1.37 | $-2.95 |
| Operating cash flow | -$113.2M | -$70.8M | -$33.5M | -$27.6M | -$42.1M |
| Free cash flow | -$113.3M | -$71.3M | -$33.6M | -$27.7M | -$42.4M |
| Cash & equivalents | $85.4M | $33.2M | $26.7M | $26.8M | $70.1M |
| Total assets | $145.8M | $200.2M | $95.9M | $126.4M | $78.7M |
| Total liabilities | $67.8M | $28.4M | $14.2M | $15.5M | $14.3M |
| Shareholders' equity | $78.1M | $171.8M | $81.7M | $110.9M | $64.4M |
Source: SEC EDGAR filings · CIK 0001374690 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.